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Serine hydroxymethyltransferase 2 (SHMT2) regulates one-carbon transfer reactions that are essential for amino acid 
and nucleotide metabolism, and uses pyridoxal-5′-phosphate (PLP) as a cofactor. Apo SHMT2 exists as a dimer with 
unknown functions, whereas PLP binding stabilizes the active tetrameric state. SHMT2 also promotes inflammatory 
cytokine signalling by interacting with the deubiquitylating BRCC36 isopeptidase complex (BRISC), although it is unclear 
whether this function relates to metabolism. Here we present the cryo-electron microscopy structure of the human 
BRISC–SHMT2 complex at a resolution of 3.8 Å. BRISC is a U-shaped dimer of four subunits, and SHMT2 sterically blocks 
the BRCC36 active site and inhibits deubiquitylase activity. Only the inactive SHMT2 dimer—and not the active PLP-bound 
tetramer—binds and inhibits BRISC. Mutations in BRISC that disrupt SHMT2 binding impair type I interferon signalling 
in response to inflammatory stimuli. Intracellular levels of PLP regulated the interaction between BRISC and SHMT2, as 
well as inflammatory cytokine responses. These data reveal a mechanism in which metabolites regulate deubiquitylase 
activity and inflammatory signalling.
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SHMT2 functions in one-carbon folate metabolism that supports 
the purine and thymine synthesis that is required for cell growth and 
proliferation. Full-length SHMT2 localizes to mitochondria through 
an N-terminal mitochondria-targeting sequence; an N-terminal trun-
cation that removes residues 1–21 generates the cytoplasmic SHMT2α 
isoform1,2 (Fig. 1a). PLP, the active form of vitamin B6, promotes a shift 
in the SHMT2 oligomeric state from an inactive dimer to the enzymat-
ically active tetramer1,3.
SHMT2 also controls inflammatory cytokine signalling through 
its interaction with the BRISC deubiquitylase (DUB). BRCC36 is a 
JAMM (JAB1, MOV34, and MPR1, PAD1 N-terminal (MPN) family) 
Zn2+-dependent DUB and functions within two macromolecular com-
plexes, which requires interaction with MPN- pseudo-DUBs Abraxas 1 
or Abraxas 2 for DUB activity4–6 (Fig. 1a). The nuclear Abraxas 1 
isopeptidase complex (ARISC) complex partners with RAP80 and 
BRCA1, and forms the BRCA1-A complex that is required for DNA 
repair7–10. Direct interaction with SHMT2 enhances the delivery of 
BRISC to ubiquitylated type I interferon (IFN) receptors (IFNAR1 and 
IFNAR2)11,12, which allows BRCC36 to deubiquitylate the lysine-63-
linked ubiquitin chains (Ub(K63)) on IFNAR1 and IFNAR2 and limits 
the endocytosis and lysosomal degradation of these receptors12. BRISC-
deficient mice exhibit attenuated IFN responses and are protected from 
pathological conditions that stem from increased levels of inflamma-
tory signalling12. The association between BRISC and SHMT2 therefore 
provides a potential link between metabolism and inflammation.
The BRCC36–Abraxas 2 complex is an obligate dimer of heterodi-
mers that is essential for DUB activity and IFN signalling13,14. Similarly, 
BRISC and ARISC are active as stable dimers of tetramers with stoi-
chiometry 2:2:2:2 (refs. 4,5,13,15). Structures of the human BRISC are 
currently unavailable, and the molecular basis for SHMT2 binding 
and regulation is unknown. We present the cryo-electron microscopy 
(cryo-EM) structure of the BRISC–SHMT2 complex at a resolution of 
3.8 Å, which reveals the BRISC architecture and the molecular basis 
of the inhibition of DUB activity by SHMT2. Structure-guided muta-
tions or increasing intracellular levels of PLP reduced the interaction 
between BRISC and SHMT2 as well as inflammatory signalling, which 
reveals a direct link between vitamin B6 metabolism and control of 
immune responses.
SHMT2 is an endogenous BRISC inhibitor
We produced SHMT2ΔN (residues 18–504), which lacks the mito-
chondria-targeting sequence and is a mixture of dimers and tetram-
ers in solution (Fig. 1b). Tetramer peak fractions absorbed strongly at 
435 nm, which indicates association with PLP and is consistent with 
previous findings that PLP binding promotes a shift from an inactive 
dimer to the active SHMT2 tetramer1 (Fig. 1c, Extended Data Fig. 1a, b). 
Dimer and tetramer peaks were confirmed by native mass spectrometry 
(Extended Data Fig. 1c).
A serendipitous SHMT2(A285T) substitution near the PLP-acceptor 
residue (K280) was identified by the Structural Genomics Consortium 
(RCSB Protein Data Bank (PDB) code 6DK3). SHMT2ΔN(A285T) 
is dimeric in solution and crystal lattice, which enables a direct com-
parison between dimer (apo enzyme) and tetramer (holoenzyme) 
structures (Extended Data Fig. 1a–d). Structures of individual wild-
type SHMT2α and SHMT2ΔN(A285T) protomers are similar, which 
suggests that the A285T substitution does not substantially perturb 
the structure (Extended Data Fig. 1e). However, the A285T substi-
tution reduces covalent PLP association, subsequent tetrameriza-
tion and catalytic activity (Extended Data Fig. 2a, b). The addition 
of PLP induced a transition from the dimer to the tetramer form of 
SHMT2ΔN, which led to a large shift in thermal melting temperature 
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in SHMT2(A285T) and SHMT2(K280A) mutants, which is consistent 
with studies that show that alterations of SHMT2 that abrogate PLP 
binding shift the equilibrium towards the dimer1,16–19 (Extended Data 
Fig. 2e).
The addition of SHMT2ΔN inhibited the DUB activity of BRISC 
(Fig. 1d). Dimeric SHMT2ΔN was a better inhibitor (half maximal 
inhibitory concentration (IC50) = 9 nM) than the tetrameric form 
(IC50 = 77.5 nM). Because the SHMT2ΔN tetramer is not fully satu-
rated with PLP (Extended Data Fig. 2c, d), preincubation with PLP fur-
ther reduced BRISC inhibition by the SHMT2ΔN tetramer (Fig. 1d). 
The obligate dimers SHMT2ΔN(A285T) and SHMT2ΔN(K280A/
A285T) were effective inhibitors of BRISC and similar to SHMT2ΔN 
dimers (Fig. 1d). SHMT2ΔN(A285T) DUB inhibition was selective for 
BRISC as compared to ARISC (Fig. 1e), which confirms that SHMT2 
does not interact with the ARISC12. These data suggest a previously 
unknown role for the dimeric (PLP-free) form of SHMT2 in regulating 
the DUB activity of BRISC.
Structure of the BRISC–SHMT2 complex
To understand the molecular basis of the BRISC–SHMT2 association, 
and how PLP-dependent SHMT2 oligomerization affects DUB activ-
ity, we solved the structure of the BRISC bound to an SHMT2 dimer. 
Using limited proteolysis, we identified a minimal complex—which we 
term BRISCΔNΔC (Extended Data Fig. 3a, b)—that contains BRCC36, 
BRCC45, MERIT40ΔN (residues 72–329) and Abraxas 2ΔC (residues 
1–267). BRISC and BRISCΔNΔC were active towards a fluorogenic 
K63-linked diubiquitin (diUb) substrate (Extended Data Fig. 3c) 
and both were inhibited by SHMT2ΔN(A285T), with similar 
IC50 values (Extended Data Fig. 3d). SHMT2ΔN(A285T) formed 
a stable equimolar complex with BRISCΔNΔC (Extended Data 
Fig. 3e, f).
We used negative-stain electron microscopy and single- 
particle cryo-EM to evaluate BRISCΔNΔC and the BRISCΔNΔC–
SHMT2ΔN(A285T) complex. BRISCΔNΔC particles showed dis-
tinct U-shaped assemblies that were similar to those seen for the 
nuclear ARISC15. However, BRISCΔNΔC showed heterogene-
ity and flexibility of the ‘arm’ regions (Extended Data Fig. 4a). The 
BRISCΔNΔC–SHMT2ΔN(A285T) complex was homogeneous, 
with SHMT2ΔN(A285T) bridging both arms of the U-shaped BRISC 
structure in two-dimensional class averages (Extended Data Fig. 4a). 
We collected a large cryo-EM dataset and identified 71,262 particles 
(approximately 11%) with a structure with apparent C2 symmetry 
that contained a central trapezoidal region and two extending arms. 
The remaining particles form a structure that is missing one arm 
(Extended Data Fig. 4b, c). After three-dimensional classification and 
refinement, using both C1 and C2 symmetry, we obtained electron 
microscopy density maps at resolutions of 3.8 Å and 4.2 Å, respectively 
(Extended Data Fig. 4c, d, Extended Data Table 1).
The BRISCΔNΔC comprises a central core region and two extend-
ing arms. We fit the structure of insect BRCC36–Abraxas 2 (PDB code 
5CW3)13 at the base of the map; the quality of the electron microscopy 
density in this region was sufficient for modelling the human BRCC36–
Abraxas 2 sequence into the structure (Fig. 2). The SHMT2ΔN(A285T) 
dimer was immediately recognizable in the electron microscopy map, 
with the structure (PDB code 6DK3) fitting directly above the MPN 
domains of BRCC36–Abraxas 2 (Fig. 2). The remaining unoccupied 
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Fig. 1 | SHMT2 dimer inhibits BRISC DUB activity. a, Domain 
architecture of SHMT2 and BRCC36-containing complexes. MTS, 
mitochondria-targeting sequence; CC, coiled coil. b, SHMT2ΔN elution 
profile after size-exclusion chromatography, monitored by measuring 
absorbance at 280 nm. SHMT2ΔN bound to PLP was detected by 
measuring absorbance at 435 nm. Data are representative of three 
independent experiments. AU, arbitrary units. c, Schematic of  
SHMT2ΔN dimer–tetramer equilibrium in response to PLP binding.  
d, BRISC DUB activity against a fluorogenic K63-linked diUb substrate in 
the presence of various forms of SHMT2ΔN. e, BRISC and ARISC DUB 
activity against a fluorogenic K63-linked diUb substrate in the presence of 
SHMT2ΔN(A285T). Data in d, e are mean ± s.e.m. of three independent 
experiments carried out in duplicate.
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density belongs to BRCC45 and MERIT40, for which no experimental 
structures are available.
BRCC45 contains two ubiquitin E2 variant (UEV) domains at its 
N and C termini. We used the FFAS0320 and HHpred21 algorithms 
to search for additional domains and identified a putative ‘UBC-like’ 
domain within residues 144–280, which suggests the presence of a 
middle UEV domain (UEV-M). Tandemly repeated domains are 
common during protein evolution, which provides reinforcement 
for the independent prediction of a third UEV domain in BRCC45 
(ref. 22) (Fig. 1a). Consistent with this hypothesis, we manually built a 
Cα-backbone structure for two consecutive UEV domains of BRCC45 
into the density that immediately extends from Abraxas 2 (Fig. 2a). 
However, owing to the low resolution of this region, precise assignment 
of the sequence was not possible.
We used the structure of the related ARISC15 as a guide to place 
homology models of MERIT40 and a third UEV (BRCC45) domain 
within the ‘fist-like’ density in the distal region of each arm (Fig. 2a). 
The resolution in this peripheral region is poor (approximately 10 Å), 
and it was therefore not possible to ascertain the precise orientation 
of the von Willebrand factor type A (vWFA) and UEV-C domains of 
MERIT40 and BRCC45, respectively. We modelled UEV-N and UEV-C 
in proximity to Abraxas 2 and MERIT40, respectively, in accordance 
with previous deletion studies4,23 (Fig. 2a). Thus, we built a complete 
BRISC–SHMT2 model using a combination of known structures, 
de novo model building and homology modelling (Fig. 2a). The ‘core’ 
structure—consisting of the BRCC36–Abraxas 2 superdimer and the 
SHMT2 obligate dimer—is well-resolved, with a local resolution of 
3.5–4.0 Å (Extended Data Figs. 4c, d, 5a, b).
SHMT2 bridges the two arms of the BRISC and sits directly above 
the BRCC36–Abraxas 2 superdimer, which explains the requirement 
for superdimer formation in SHMT2 binding13. SHMT2 interacts with 
MPN domains of BRCC36 and Abraxas 2, and UEV-N and UEV-M 
domains of BRCC45 (Fig. 2a). The main BRISC-interacting surface on 
SHMT2 is centred on the two α6 helices; proximal residues between 
SHMT2–Abraxas 2, SHMT2–BRCC36 and Abraxas 2–BRCC45 are 
shown in Fig. 2b. MERIT40 does not contact SHMT2 directly (Fig. 2a), 
and its position may provide stabilizing interactions with BRCC45 
while also interacting with other signalling molecules24. A comparison 
between human and insect BRCC36–Abraxas 2 superdimers reveals 
a similar overall structure, with minor local shifts (Extended Data 
Fig. 5c–e). Overall, the structure provides a view of the interaction 
surfaces between SHMT2 and components of the BRISC.
Previous work suggested that the BRISC also interacts with SHMT1 
in cells, although cellular BRISC–SHMT2 complexes were much more 
abundant12. To test whether SHMT2 and SHMT1 interact equally with 
BRISC in vitro, we purified SHMT1 dimers and tetramers; we failed 
to assemble BRISC–SHMT1 complexes and observed no inhibition 
of BRISC DUB activity in vitro (Extended Data Fig. 6). Although it 
remains possible that BRISC–SHMT1 complexes form in cells, we pre-
dict these will be of lower affinity in comparison with BRISC–SHMT2 
complexes, and may be a consequence of indirect interactions with 
other factors.
We altered SHMT2 residues in proximity to BRISC (Fig. 2b), and 
assessed their effects on DUB activity in vitro. Residue substitutions 
were made in the SHMT2ΔN(A285T) background, which purifies 
as a dimer (Extended Data Fig. 7a, b). SHMT2ΔN(A285T) vari-
ants containing L211R or L215R were each less-potent inhibitors of 
BRISC DUB activity as compared to SHMT2ΔN(A285T), and the 
SHMT2ΔN(A285T/L211R/L215R) mutant had no detectable inhib-
itory effect on BRISC activity (Extended Data Fig. 7c). SHMT2ΔN 
inhibition was also observed with hexa-ubiquitin (hexaUb) chains as 
substrates (Extended Data Fig. 7d). DUB activity was only margin-
ally reduced when assayed with SHMT2ΔN(A285T/L211R/L215R), 















































































Fig. 2 | Structure of the BRISC–SHMT2 complex. a, Cryo-EM density 
at contour level of 0.055 (C2 map), shown in transparent surface. Proteins 
are depicted as cartoon models. Owing to low resolution in the extended 
arm regions, UEV-C (BRCC45) and vWFA (MERIT40) models are shown 
for size comparison only. b, Close-up view of BRISC–SHMT2 interfaces. 
Residues labelled in red were altered in validation analysis.
N A T U R E | www.nature.com/nature
ArticlereSeArcH
fluorescently labelled diUb and is consistent with the observation that 
the L211R/L215R double substitution reduces BRISC–SHMT2 inter-
action in vitro (Extended Data Fig. 8a). These experiments establish 
the SHMT2 α6 helix as the most important contact surface for BRISC 
interaction and inhibition of DUB activity.
BRISC–SHMT2 affects immune signalling
To understand the relevance of the BRISC–SHMT2 interaction in 
cells, we altered interface residues between SHMT2, Abraxas 2 and 
BRCC45 (Fig. 2b) and assessed interactions by co-immunopre-
cipitation (Fig. 3a, b). Consistent with the loss of interaction with 
SHMT2, the Abraxas 2 mutants A142R, E144A and E144R expressed 
in Abraxas2-/- mouse embryonic fibroblasts (MEFs) showed reduced 
STAT1 phosphorylation in response to infection with herpes simplex 
virus (HSV); this was also true for N100R, Y107R and D23R mutants, 
which either reduce or prevent BRCC45–MERIT40 binding (Fig. 3c). 
The BRISC–SHMT2 interaction was also required for immune sig-
nalling when cells were challenged using lipopolysaccharide (LPS) or 
IFNβ (Fig. 3d). Moreover, we observed increased IFNAR1 ubiquityl-
ation after IFN stimulation in cells that overexpressed the Abraxas 2 
E144R mutant (Extended Data Fig. 7e).
For a broader view of immune signalling output that is dependent 
on the BRISC–SHMT2 complex, we performed quantitative PCR 
with reverse transcription (qRT–PCR) analysis of 79 genes that 
are often upregulated during a type I interferon response. Ectopic 
expression of wild-type Abraxas 2 resulted in 48 genes being upregu-
lated between 2- and 8,000-fold in response to LPS (Fig. 3e, Extended 
Data Fig. 9a). Accordingly, LPS challenge of Abraxas2–/– cells or 
Abraxas2–/– cells ectopically expressing Abraxas 2(E144R) showed a 
poor response, with 11 and 8 genes, respectively, being upregulated 
between two- and tenfold compared to non-challenged Abraxas2–/– 
cells (Fig. 3e).
We next altered SHMT2 residues to ascertain their importance in 
cellular assembly of BRISC–SHMT2 complexes. Overexpression of 
SHMT2ΔN(L211R/L215R) resulted in the loss of BRISC–SHMT2 
interaction in MEFs, which mirrors the results seen in vitro (Extended 
Data Figs. 7f, 8a). Levels of STAT1 phosphorylation were also affected 
in cells that were challenged with LPS (Extended Data Fig. 7g), and 
we observed increased IFNAR1 ubiquitylation after IFN stimula-
tion of cells that overexpress the SHMT2ΔN(L211R/L215R) mutant 
(Extended Data Fig. 7e). Collectively, these findings reveal the specific 
Abraxas 2 and SHMT2 surfaces that are required for BRISC–SHMT2 
complex assembly and immune signalling in cells.
The positioning of SHMT2 within the structure provides a potential 
rationale for its inhibition of DUB activity, as it blocks the BRCC36 
active site (Extended Data Fig. 8b). Kinetic data suggest SHMT2 acts 
as an apparent competitive inhibitor (Extended Data Fig. 8c). However, 
the increase in Km was only moderate (about twofold at equimolar 
BRISC-SHMT2 complex), which suggests that Ub(K63) chains 
might displace bound SHMT2 from BRISC when poly-ubiquitylated 
substrates are in close proximity. This model would account for the 
counterintuitive function of SHMT2 as both an inhibitor of BRISC 
activity and an essential mediator of BRISC association with sites of 
DUB action (Extended Data Fig. 10). It is also possible that other factors 
and post-translational modifications trigger SHMT2 dissociation from 
BRISC in cells. We propose that SHMT2 acts as a reversible endogenous 
BRISC inhibitor that prevents non-specific DUB activity. This regulated 
safety mechanism is similar in concept to protease inhibition by endog-
enous inhibitors25. To our knowledge, SHMT2 is the first example of an 
endogenous DUB inhibitor, which acts as a precedent for the possible 
regulation of other DUBs in vivo.
Regulation of BRISC–SHMT2 interaction by PLP
BRISC DUB inhibition provides the first non-enzymatic role of the 
SHMT2 dimer. Our structure explains why the apo SHMT2 dimer—
but not the PLP-bound tetramer—inhibits DUB activity. The SHMT2 
α6 helix interacts with BRISC, and this interaction interface overlaps 
with the SHMT2 tetramerization surface; this accounts for the observa-
tion that the SHMT2 tetramer and the BRISC–SHMT2 complexes are 
mutually exclusive (Extended Data Figs. 1b, 8d). The SHMT2ΔN–PLP 
tetramer does not form BRISC–SHMT2 complexes in vitro (Extended 
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Fig. 3 | BRISC–SHMT2 interaction is important for interferon 
signalling. a, b, Immunoprecipitation was performed using anti-
Flag antibody in HEK293T cells transiently transfected with Flag–
haemagglutinin (HA) epitope-tagged Abraxas 2 wild type (WT) or 
mutants. Immunoblotting was performed for the indicated proteins. UTF, 
untransfected cells. c, Abraxas2–/– (KO) MEFs and Abraxas2–/– MEFs 
stably reconstituted with wild-type or mutant Abraxas 2 were infected  
with HSV that lacks the lytic phase gene ICP0. IFN signalling was  
assessed by immunoblotting for STAT1 phosphorylated at Y701 (pSTAT1). 
d, Wild-type MEFs that overexpress wild-type Abraxas 2 (WT +WT) or 
Abraxas 2(E144R) (WT +E144R) were challenged with LPS and IFNβ. 
IFN signalling was assessed as in c. Data in a–d are representative of three 
independent experiments. For gel source data, see Supplementary Fig. 1.  
e, Volcano plots illustrating the fold change in gene expression of IFN-type 
I-stimulated genes relative to Abraxas2–/– MEFs without LPS treatment.  
P values were calculated using a Student’s t-test (two-tailed distribution 
and equal variances between the two samples) on the triplicate 2-ΔCt values 
for each gene in each treatment group compared to the control group. 
Genes below the P = 0.05 threshold were upregulated in wild type with 
LPS, but represented as below statistical significance owing to the relative 
expression in Abraxas2–/–samples being almost zero. Regulated genes are 
highlighted in Extended Data Fig. 9a.
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regulate SHMT2 dimer availability and BRISC–SHMT2 complex 
formation in cells.
To test this hypothesis, we cultured MEFs and HEK293T cells in 
B6-vitamer-free medium, and compared the BRISC–SHMT2 inter-
action after pyridoxal supplementation (Fig. 4a). PLP levels were con-
firmed by vitamin B6 metabolite measurements in whole-cell lysates 
(Fig. 4b), and fewer SHMT2 dimers were present after pyridoxal 
supplementation (Extended Data Fig. 9b). This coincided with a 
marked reduction of overexpressed SHMT2ΔN and endogenous 
Abraxas 2 interaction (Fig. 4a). Similarly, the interaction between over-
expressed Abraxas 2 and endogenous SHMT2 was reduced (Fig. 4c). 
The PLP-dependent reduction of BRISC–SHMT2 interaction was not 
observed when PLP-resistant SHMT2 mutants were expressed (Fig. 4d).
We next measured levels of STAT1 phosphorylation, and observed a 
pyridoxal-dependent reduction of phosphorylated STAT1 upon IFNβ 
stimulation (Fig. 4e, Extended Data Fig. 9c). This reduction was not 
observed when PLP-resistant SHMT2 mutants were expressed (Fig. 4e, 
Extended Data Fig. 9d). Consistently, we observed an increase in both 
BRISC–SHMT2 complexes (Fig. 4d, Extended Data Fig. 9e) and levels 
of STAT1 phosphorylation when PLP-resistant SHMT2 mutants were 
expressed in cells cultured in B6-vitamer-containing medium and chal-
lenged with IFNβ or HSV (Fig. 4e, Extended Data Fig. 9d, f). Finally, 
we observed a pyridoxal-dependent reduction of nine IFN-induced 
genes in LPS-challenged MEFs that stably express SHMT2ΔN, but 
saw no change in MEFs in which a PLP-resistant mutant was expressed 
(Fig. 4f). IL10 was upregulated by 2.1-fold in pyridoxal-supplemented 
SHMT2ΔN cells (Fig. 4f) but not in LPS-stimulated MEFs containing 
wild-type Abraxas 2, which suggests that IL10 is not directly dependent 
on BRISC–SHMT2 (Extended Data Fig 9a). These experiments provide 
further evidence that PLP binding to SHMT2 regulates the BRISC–
SHMT2 interaction and immune signalling in cells.
Endogenous small-molecule ligands that control ubiquitin 
signalling could be physiologically important. The influence of PLP 
on BRISC activity establishes a regulatory precedent for DUBs, akin 
to the plant hormone auxin and the second messenger inositol hex-
akisphosphate, which together allosterically regulate the activity of E3 
ubiquitin ligases26. Post-translational modifications of the PLP accep-
tor-lysine27,28 could provide additional layers of regulation of BRISC–
SHMT2 association and immune signalling. It is possible that natural 
and synthetic SHMT2 binders—such as folate and PLP analogues—
can modulate dimeric SHMT2 availability or conformation, and thus 
interferon signalling (Extended Data Fig. 10). Understanding the reg-
ulatory mechanisms of BRISC–SHMT2 interactions may therefore 
be useful for unlocking the potential of small-molecule ligands as 
therapeutic agents.
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Fig. 4 | PLP regulation of BRISC-SHMT2 interaction and signalling. 
a, Immunoprecipitation of stably expressed Flag–HA epitope-tagged 
SHMT2ΔN using an anti-Flag antibody. Immunoblotting was performed 
after pyridoxal (PL) treatment for 48 h. b, Gas chromatography–mass 
spectrometry measurements of B6 vitamers from whole-cell lysates after 
culturing for 48 h in B6-vitamer-free medium, with and without pyridoxal. 
PN, pyridoxine. c, Immunoprecipitation of ectopically expressed 
Abraxas 2 using an anti-Flag antibody in MEFs grown in B6-vitamer-
free medium for 48 h. Immunoblotting was performed for the indicated 
proteins after addition of 20 μM pyridoxal and/or 500 units per millilitre 
of mouse IFNβ. d, Immunoprecipitation using an anti-Flag antibody in 
MEFs stably expressing various Flag–HA epitope-tagged forms of SHMT2. 
Immunoblotting was performed after treatment with 20 μM pyridoxal for 
48 h. e, Phosphorylated STAT1 levels in MEFs stably expressing various 
forms of SHMT2, and cultured in B6-vitamer-free medium. Cells were 
treated with 20 μM pyridoxal and/or 500 units per millilitre of IFNβ for 
48 h. Data in a, c–e are representative of three independent experiments. 
For gel source data, see Supplementary Fig. 1. f, Volcano plots comparing 
type-1-IFN-induced gene expression in MEFs stimulated with LPS and 
cultured in the absence (PL-) or presence (PL+) of 20 μM pyridoxal.  
P values were calculated using a Student’s t-test (two-tailed distribution 
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values for each gene in each treatment group compared to the control 
group.
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No statistical methods were used to predetermine sample size. The experiments 
were not randomized and investigators were not blinded to allocation during 
experiments and outcome assessment.
Cloning, protein expression and purification of BRISC–SHMT2 complex and 
SHMT1. Genes for the four-subunit human BRISC were cloned in the MultiBac 
system used for co-expression of multiprotein complexes in insect cells (Sf9)29. 
A single 6×His purification tag followed by a cleavable TEV site was engineered 
at the N terminus of BRCC45. Virus preparation, protein production and protein 
purification were performed as previously described13.
Wild-type and mutant forms of human SHMT2ΔN (residues 18–504) and 
SHMT1 were cloned in a pProEx-HTb vector and expressed in Escherichia coli 
BL21 (DE3) codon plus RIL in Terrific Broth (TB) in the presence of 100 μg/ml 
ampicillin and 34 μg/ml chloramphenicol at 37 °C to an optical density at 600 nm 
(OD600) of 1.0–1.2 arbitrary units (AU). Cells were then induced with 0.5 mM iso-
propyl-1-thio-d-galactopyranoside (IPTG) and incubated overnight at 18 °C. Cells 
were collected by centrifugation at 5,500g and cell pellets were resuspended in lysis 
buffer (50 mM Tris-HCl, pH 7.6, 300 mM NaCl, 20 mM imidazole, 0.075% β-mer-
captoethanol, 5% glycerol, 1 mM benzamidine, 0.8 mM phenylmethyl sulfonyl 
fluoride (PMSF) and 0.3 mg/ml lysozyme). Cells were lysed by sonication (1-s on, 
3-s off for a total of 16 min) on ice and the lysates were cleared by centrifugation 
at 26,000g. The clarified lysate was loaded onto a 5-ml chelating FastFlow column 
(GE Healthcare), charged with Ni2+. The column was washed with 4 column 
volumes (CV) of wash buffer consisting of 50 mM Tris-HCl (pH 7.6), 500 mM 
NaCl, 20 mM imidazole, 0.075% β-mercaptoethanol and 1 mM benzamidine, and 
the protein was eluted by applying an imidazole gradient with elution buffer con-
sisting of 50 mM Tris-HCl (pH 7.6), 300 mM NaCl, 300 mM imidazole, 0.075% 
β-mercaptoethanol and 1 mM benzamidine. The fractions containing SHMT2ΔN 
or SHMT1 were pooled and dialysed against buffer containing 20 mM MES, pH 
6.5, 250 mM NaCl, 5% glycerol, 20 mM imidazole, 0.075% β-mercaptoethanol 
and 1 mM benzamidine. TEV was added to the protein sample and incubated 
overnight at 4 °C. Dialysed protein was loaded on a 16/600 Superdex200 column 
(GE Healthcare), equilibrated with 20 mM MES (pH 6.5), 500 mM NaCl and 
2 mM TECP.
BRISCΔNΔC and SHMT2ΔN(A285T) were mixed in vitro at 1:4 molar 
ratio and incubated on ice for 40 min. The mixture was then injected onto a 
Superdex 10/300 S200 column and peak fractions were analysed by sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE). Fractions con-
taining the BRISCΔNΔC–SHMT2ΔN(A285T) complex were pooled, and the 
BRISC–SHMT2ΔN(A285T) complex was used immediately for grid preparation 
and electron microscopy analysis, as described below. The remaining BRISC–
SHMT2ΔN(A285T) complex was pooled and stored at -80 °C at a final concen-
tration of 0.5 mg/ml. Denatured and native masses of all protein preparations were 
verified by mass spectrometry.
Negative-stain electron microscopy. BRISCΔNΔC and BRISCΔNΔC–
SHMT2ΔN(A285T) complexes were diluted in buffer (25 mM HEPES, pH 7.5, 
150 mM NaCl, 1 mM TCEP) to 0.0041 mg/ml and 0.0051 mg/ml, respectively, 
immediately before grid preparation. Glow-discharged, 300-mesh carbon-coated 
copper grids (Agar Scientific) were incubated with 7 μl BRISCΔNΔC or 
BRISCΔNΔC–SHMT2ΔN(A285T) for 60 s, passed through 3 droplets of water 
and stained twice with 2% w/v uranyl acetate for 20 s and 10 s, respectively. Excess 
liquid was removed by blotting. Micrographs were collected on an FEI Tecnai 
F20 electron microscope operated at 120 kV equipped with an FEI Ceta CMOS 
camera. Data processing was carried out using RELION 2.1. Initially, ~1,500 
particles were picked manually and extracted with a 450 Å2 box size. Particles 
were subjected to reference-free 2D classification to generate initial references for 
auto-picking. A total of 28,566 and 26,824 particles were picked for the BRISCNΔC 
and BRISCΔNΔC–SHMT2ΔN(A285T) complexes, respectively. One round of 
reference-free 2D classification was then carried out for each.
Cryo-grid preparation and data collection. BRISCΔNΔC–SHMT2ΔN(A285T) 
complex was diluted to 0.05 mg/ml in buffer (25 mM HEPES, pH 7.5, 150 mM 
NaCl, 1 mM TCEP) immediately before grid preparation. Cryo-EM grids were 
prepared by placing 3 μl of this complex onto glow-discharged, 200-mesh copper 
grids (Quantifoil R1.2/1.3), followed by immediate blotting and plunge-freez-
ing in liquid ethane cooled by liquid nitrogen, using an FEI Vitrobot IV at 95% 
relative humidity, chamber temperature of 4 °C. Datasets were collected on an FEI 
Titan Krios transmission electron microscope at 300 kV, using a total electron dose 
between 83 and 95 e– per Å2, a magnification of 75,000× and a final calibrated 
object sampling of 1.065 Å per pixel. Three independent datasets, giving a total 
of 7,494 movies, were recorded using the EPU automated acquisition software 
on an FEI Falcon III direct electron detector30. Each exposure movie had a total 
exposure time of 2 s collected over 70–79 frames with an electron dose of 1.2 e- 
per A2 per frame. Detailed information on data collection is shown in Extended 
Data Table 1.
Image processing. A schematic of the data processing pipeline is shown 
in Extended Data Fig. 4. Image processing was carried out using RELION 3.031. 
Drift-corrected averages of each movie were created using MOTIONCORR232 and 
the contrast transfer function of each determined using gCTF33. Initially, ~2,000 
particles for each dataset were manually picked, extracted with a box size of 373 Å2 
and subjected to reference-free 2D classification to generate initial references for 
auto-picking. After auto-picking, each dataset was individually subjected to itera-
tive rounds of reference-free 2D classification. Based on visual inspection, quality 
2D average classes were selected for each dataset and then the three sets were 
combined. An initial model generated ab initio from the 2D class averages of the 
BRISCΔNΔC–SHMT2 negative-stain data, filtered to ~60 Å, was used for initial 
3D classification of the combined dataset. Of the eight classes generated, one con-
tained particles comprising the intact complex—that is, the BRCC36–Abraxas 2–
SHMT2 core and both BRCC45–MERIT40 arms. This class was processed as a 
separate dataset consisting of 71,262 particles, representing the complete, two-arm 
structure. In parallel, this class—along with four others (totalling 514,930 parti-
cles)—was processed to represent the complete dataset. Both were subjected to a 
final round of 3D classification to remove any remaining ‘bad’ particles. The best 
classes from 3D classification were taken forward and subjected to 3D refinement, 
per-particle CTF correction and particle polishing31. C2 symmetry was imposed to 
the two-arm dataset. Post-processing was used to appropriately mask the model, 
estimate and correct for the B-factor of the maps. Final resolutions were deter-
mined using the gold-standard Fourier shell correlation criterion (FSC = 0.143). 
Local resolution was estimated using the local resolution feature in RELION.
Model building and refinement. A preliminary model for the BRISCΔNΔC–
SHMT2ΔN(A285T) complex was generated using a combination of known 
crystal structures (BRCC36–Abraxas 2 superdimer from Camponotus floridanus 
(PDB code 5CW3) and human SHMT2 dimer (PDB code 6DK3)) and homology 
models generated by Phyre234 (BRCC45, consisting of two UEV domains, and 
MERIT40). This initial model was manually fitted into the electron microscopy 
density map for the C1 reconstruction (3.8 Å) using rigid-body fitting in UCSF 
Chimera35. The model was then manually fitted and rebuilt in COOT36 to trace 
the human sequences of BRCC36 and Abraxas 2. Amino acid residues that lacked 
unambiguous density were deleted or modelled up to their Cβ position while 
preserving sequence information. The Cα backbone for BRCC45 UEV-N and 
UEV-M was traced into the remaining density mainly as alanine and glycine resi-
dues, and the precise sequence for BRCC45 could not be modelled with confidence. 
Gaps numbered arbitrarily were left where direct connectivity between secondary 
structure elements could not be determined.
The higher-resolution C1 map was used for model building and the two-arm 
model was generated by using the two-fold symmetry of the superdimer core.
The model was refined against the C1 and C2 maps in Phenix37 using default 
parameters and secondary structure restraints. The overall quality of the model 
was assessed using MolProbity38. Fitting of the remaining BRCC45 UEV-C and 
MERIT40 domains into the peripheral parts of the C2 electron microscopy map 
was carried out using rigid-body fitting in Chimera; these are displayed for relative 
position and size comparison purposes only.
DUB activity assays. BRISC complexes were assayed at 30 °C in DUB reaction 
buffer containing 50 mM HEPES-NaOH pH 7.0, 100 mM NaCl, 0.1 mg/ml BSA, 
1 mM DTT and 0.005% Tween-20. Internally quenched fluorescent (IQF) K63-
linked diUb (Lifesensors, catalogue number: DU6303) was used as a reporter for 
DUB activity (1 part IQF diUB to 9 parts unlabelled K63-linked diUb, prepared as 
previously described39). Twenty-microlitre enzyme reactions were carried out in 
384-well black flat-bottom low-flange plates (Corning; 35373). Cleaved diUb was 
monitored by measuring fluorescence intensity (excitation, 540 nm; emission, 580 
nm; dichroic mirror, 560 nm) every 1 min over 20 min, and initial velocity (vo) was 
calculated as the slope of the linear part of the reaction-progress curve. 
Fluorescence intensity units were converted to nM product concentration using 
TAMRA-labelled ubiquitin (Lifesensors, catalogue number: SI270T) as a standard. 
Enzyme concentrations for which a reasonable progress curve was obtained over 
20 min were: 1 nM BRISC and 40 nM ARISC. Substrate concentration was 300 
nM. IC50 values were calculated by fitting the data using the GraphPad Prism 
built-in dose–response equation for inhibition with variable slope: 
= + − + − ×y bottom (top bottom) (1 10 )x h((log(IC ) ) )50 . Michaelis–Menten anal-
ysis in the absence and presence of increasing concentrations of SHMT2 was per-
formed in DUB buffer containing 50 mM HEPES-NaOH (pH 6.8), 100 mM NaCl 
and 5 mM DTT. BRISC concentration was 1.5–2.0 nM and IQF K63-linked diUb 
was used (0–4 μM) as substrate (concentrations greater than 4 μM inhibited BRISC 
activity). Data were fit using the standard Michaelis–Menten equation, constrain-
ing Vmax to be less than the Vmax in the absence of SHMT2. Lineweaver–Burk plots 
and Michaelis–Menten analysis were performed using GraphPad Prism.
K63-linked hexaUb chains were also used to determine DUB activity. 
Sixty-microlitre reactions were carried out in 1.5 ml Eppendorf tubes at 30 °C 
in DUB reaction buffer. BRISC was incubated in the presence or absence of 
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SHMT2ΔN or SHMT1 forms for 30 min at room temperature, before the addi-
tion of hexaUb(K63). Reactions containing 0.5 nM BRISC, 2 μM SHMT and 
1 μM hexaUb(K63) were incubated for 1 h. Immunoblotting was performed with 
commercially available HRP-conjugated antibody to Ub (P4D1, Santa Cruz).
SHMT2 PLP association and enzyme activity assays. PLP association assays were 
performed in 20-μl reactions in 384-well plates (Greiner) in buffer containing 50 
mM HEPES-Na (pH 7.8), 50 mM NaCl, 50 mM KCl, 5% glycerol, 0.2 mM DTT, 
0.1 mM EDTA and 0.005% Tween-20. SHMT2ΔN and point mutants (5 μM) were 
rapidly mixed with PLP (100 μM) and the reaction was monitored by measuring 
absorbance at 435 nm (every 30 s over 1 h) using a Hidex Sense microplate reader.
SHMT2ΔN enzyme activity was monitored in 20-μl reactions in 384-well, 
UV-transparent plates (Greiner). The synthetic substrate l-threo-phenylserine 
(2S,3R)-2-amino-3-hydroxy-3-phenylpropionic acid (BACHEM) was used as 
previously described40 with minor modifications. Reactions were performed in 
buffer containing 50 mM HEPES-Na (pH 7.5), 100 mM NaCl, 0.5 mM TCEP 
and 0.005% Tween-20. SHMT2ΔN and point mutants (2 μM) were preincubated 
with 200 μM PLP for 1 h at 25 °C. Five microlitres of enzyme–PLP solution was 
added to 15 μl of solution containing 0–260 mM l-threo-phenylserine, and the 
reaction was monitored by measuring absorbance of benzyldehyde at 279 nm in a 
Hidex Sense microplate reader (every 2 min over 20 min). Absorbance units were 
converted to molar concentrations using a standard curve of known concentrations 
of benzyldehyde solutions (Sigma). Initial velocity (vo) was calculated as the slope 
of the linear part of the reaction progress curve (20 min).
Differential scanning fluorimetry. Thermal-shift assays were performed using an 
Applied Biosystems StepOnePlus Real-Time PCR instrument and a standardized 
differential scanning fluorimetry procedure41. Proteins were diluted in 50 mM Tris-
HCl (pH 7.4) and 100 mM NaCl to a concentration of 5 μM, and then incubated 
with the indicated concentration of compound in a total reaction volume of 10 μl, 
with final concentration of 2% (v/v) DMSO. SYPRO Orange (Invitrogen) was used 
as a fluorescence probe. The temperature was raised in regular 0.3-°C intervals 
from 25 °C to 95 °C. Compound binding experiments were assessed in duplicate 
and reported relative to DMSO controls. Normalized data were processed using 
the Boltzmann equation to generate sigmoidal denaturation curves, and Tm/ΔTm 
values were calculated as previously described41.
Native mass spectrometry. BRISCΔNΔC–SHMT2ΔN(A285T) (2.6 μM) and 
SHMT2ΔN and various mutants (2–20 μM) were buffer-exchanged into 0.2–1 
M ammonium acetate (pH 7.2) using Zeba Spin 7K MWCO desalting columns 
(ThermoFisher). Samples were analysed by nano-electrospray ionization mass 
spectrometry using either a quadrupole-IMS-orthogonal time-of-flight (TOF) mass 
spectrometer (Synapt HDMS, Waters UK), operated as previously described42, or a 
quadrupole orbitrap mass spectrometer modified for transmission of high m/z ions 
(Q-Exactive Plus, ThermoScientific), operated as previously described43,44. Both 
used gold- and palladium-coated nanospray tips prepared in-house. Data from 
the Synapt were processed using the MassLynx v4.1 suite of software supplied with 
the mass spectrometer, and UniDec v2.7.145. Data from the Q-Exactive Plus were 
processed using Xcalibur Qual Browser v4.0.27.19 and UniDec v2.7.1.
Analytical size-exclusion chromatography. Full-length BRISC and SHMT2ΔN 
or SHMT1 forms were mixed in vitro at 1:1 molar ratio (~6 μM) and incubated on 
ice for 30 min. The mixture was then injected onto a 2.4-ml Superose 6 analytical 
size-exclusion column. Peak fractions were analysed by SDS–PAGE. Controls for 
each protein were also run.
Immunoprecipitation and immunoblots. All immunoprecipitations were per-
formed as previously described46. In brief, BRCC36- and Abraxas-2-expressing cells 
were lysed in NETN 150 (0.5% NP40, 25 mM Tris pH 7.5, 150 mM NaCl, 0.5 mM 
EDTA with 1mM PMSF). Flag immunoprecipitations were performed on lysate 
supernatants for 4 h with agarose-conjugated anti-Flag M2 beads (Sigma) before 
elution in 0.1 mM glycine (pH 2.5). Immunoblots were performed with the fol-
lowing rabbit polyclonal antibodies at 1:1,000 dilution that were generated to 
recombinant proteins: MERIT40, Abraxas 2, BRCC36 and BRCC45. Commercially 
available antibodies to the HA epitope (HA.11 Covance) and SHMT2 
(Cell Signaling) were used according to the manufacturer’s directions. An 
Abraxas 2 deletion mutant (DM1) was used as control, as previously described12.
For assessment of IFNAR1 ubiquitylation in cells, cells were lysed in buffer con-
taining 2% SDS, 150 mM NaCl, 10 mM Tris-HCl, pH 8.0, 50 mM sodium fluoride, 
10mM N-ethylmaleimide and protease inhibitors. After boiling for 10 min, cell 
lysates were further diluted in immunoprecipiation buffer (10 mM Tris-HCl, pH 8.0, 
150 mM NaCl, 2 mM EDTA, 1% Triton X-100). IFNAR1 was immunoprecipi-
tated with a corresponding antibody (Bethyl Laboratories A304-290A). Resulting 
samples were separated by SDS–PAGE and analysed by immunoblotting using the 
anti-ubiquitin antibody (Lifesensor, VU101).
Response to HSV infection, LPS and IFNβ. HSV lacking the ICP0 gene was used 
to infect cells at a multiplicity of infection of 0.1 for 2 h. Medium was then changed 
followed by a 5-h incubation period. Cells were then lysed in NETN150 and lysates 
were run on a 4–12% gradient SDS–PAGE gel for immunoblot. Phosphorylated 
STAT1 and STAT1 antibodies were purchased from Cell Signaling Corporation and 
used according to the manufacturer’s specifications. Monitoring of phosphorylated 
STAT1 after LPS or IFNβ treatment was performed using conditions similar to 
those previously described12.
Cellular PLP level manipulation and validation. MEFs or HEK293T cells were 
cultured in B6 vitamer-free Dulbecco’s modified Eagle’s medium (DMEM, from 
Gibco), B6-vitamer-free DMEM + 20 μmol/l pyridoxal hydrochloride (Sigma) or 
B6-vitamer-free DMEM + 50 μmol/l pyridoxal hydrochloride. All medium was sup-
plemented with 10% FBS. After 48 h of culture, cells were collected and snap-frozen 
in liquid nitrogen. Pyridoxal, pyridoxal phosphate and pyridoxine levels were meas-
ured using liquid chromatography–mass spectrometry as previously described47.
qRT–PCR analysis of gene expression in MEFs. IFN-type I-related gene expression 
was analysed in Abraxas2–/– MEFs after treatment with LPS or vehicle control. Gene 
expression was performed in Abraxas2−/− MEFs and compared to derivative lines 
that had been stably reconstituted with Abraxas 2 wild type or mutant E144R using 
retroviral transduction. Following 16 h of LPS exposure, cells were directly lysed 
in TRIzol (Thermo Fisher Scientific) and RNA was extracted using Quick-RNA 
Miniprep Kit (Zymo Research) as per the manufacturer’s instructions. Four hun-
dred nanograms of eluted RNA was converted to cDNA using RT2 First Strand Kit 
(Qiagen). Next, the cDNA was mixed with RT2 SYBR Green Mastermix (Qiagen). 
The mouse IFN I RT2 Profiler PCR Array (Qiagen cat. no. PAMM-016Z) was per-
formed and relative expression determined using the ∆∆Ct method and normalized 
for four housekeeping genes according to manufacturer’s guidance. Single meas-
urements of three biological repeats were performed. Total results were analysed 
and compared to the gene signature of Abraxas2–/– MEFs, with and without LPS 
treatment. Gene-expression analysis of MEFs cultured in B6-vitamer-free DMEM 
with and without 20 μM pyridoxal hydrochloride was performed as above.
Reporting summary. Further information on research design is available in 
the Nature Research Reporting Summary linked to this paper.
Data availability
Coordinates have been deposited in the Protein Data Bank, code 6R8F. Cryo-EM 
reconstructions in C1 and C2 have been deposited in the Electron Microscopy Data 
Bank, codes EMD-4759 and EMD-4760. Any other relevant data are available from 
the corresponding authors upon reasonable request.
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RMSD = 0.8 Å over 414 Cα atoms
Extended Data Fig. 1 | SHMT2 exists in a dimer–tetramer equilibrium. 
a, Structure of SHMT2ΔN(A285T) dimer (PDB code 6DK3). Unbiased 
electron density maps are coloured green. The structure was erroneously 
deposited by the Structural Genomics Consortium (SGC) as wild type with 
PDB code 3OU5. It was corrected and redeposited with PDB code 6DK3 
on 28 May 2018. b, Structure of wild-type SHMT2α tetramer (PDB code 
4PVF) bound to PLP. Regions in red show structural rearrangements upon 
PLP binding. c, Native mass spectrometry spectra (single measurement 
experiment) of different forms of SHMT2ΔN (top) and measured and 
calculated masses (bottom). Calculated masses nearest to the measured 
masses are underlined. d, Size-exclusion chromatography profiles of 
different forms of SHMT2ΔN (top) and a Coomassie-stained SDS–PAGE 
gel (bottom). Data are representative of three independent experiments.  






























Extended Data Fig. 2 | PLP regulates SHMT2 dimer-tetramer 
transition. a, PLP association with the indicated forms of SHMT2ΔN. 
SHMT2–PLP internal aldimine linkage was monitored by measuring 
absorbance at 435 nm after rapid mixing of SHMT2ΔN (5 μM) and PLP 
(100 μM). Data are mean ± s.e.m. of four independent reactions.  
b, Enzyme activity of the indicated forms of SHMT2ΔN (0.5 μM) against 
the synthetic substrate l-threo-phenylserine in the presence of 50 μM PLP. 
The reaction was monitored by measuring benzyldehyde absorbance at 
279 nm. Data are mean ± s.e.m. of three independent experiments carried 
out in duplicate. c, Differential scanning fluorimetry analysis of different 
forms of SHMT2ΔN in the presence and absence of PLP. SHMT2ΔN 
wild-type and mutant proteins (5 μM) were incubated with the indicated 
concentrations of PLP or 100 μM 2-hydroxy-6-methylpyridine-3-
carboxylic acid (HMCA) for 10 min at 20 °C before differential scanning 
fluorimetry analysis. d, Changes in melting temperatures (ΔTm) for each 
of the conditions shown in c. ΔTm was calculated by subtracting the Tm of 
SHMT2 with buffer without ligands from the Tm of SHMT2 with added 
ligands. Data in c, d represent a single experiment carried out in duplicate. 
e, Summary of SHMT2ΔN(A285T) dimer–tetramer equilibrium in 














































































































Measured mass: 388759.7 Da    
Calculated mass: 388670.4 Da 

















Extended Data Fig. 3 | Reconstitution of BRISC–SHMT2 complex.  
a, Summary of limited proteolysis and Edman sequencing results 
indicating trypsin protease-labile regions for the BRCC45–MERIT40 
complex (left) and the BRISC (right). Protease cleavage sites are shown 
as scissors. Unstructured Abraxas 2 regions are indicated as dashed 
lines. b, SDS–PAGE of BRISC and BRISCΔNΔC (representative of 
three independent experiments). c, DUB activity of BRISC (full length) 
and BRISCΔNΔC (truncated) against a fluorogenic K63-linked diUb 
substrate. Data are mean ± s.e.m. of three independent experiments 
carried out in duplicate. d, SHMT2ΔN(A285T) inhibition of BRISC and 
BRISCΔNΔC DUB activity. Data are mean ± s.e.m. of three independent 
experiments carried out in duplicate. Ninety-five per cent confidence 
intervals are shown in square brackets. e, Size-exclusion chromatography 
of the BRISCΔNΔC–SHMT2ΔN(A285T) complex (top) and 
Coomassie-stained SDS–PAGE of peak fractions (bottom). f, Native mass 
spectrometry of the BRISCΔNΔC–SHMT2ΔN(A285T) complex. Data in 
e, f are representative of three independent experiments.
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Extended Data Fig. 4 | Electron microscopy analysis of BRISC and 
BRISC–SHMT2 complex. a, Negative-stain electron microscopy analysis. 
Selected 2D-averaged classes of BRISCΔNΔC (left) and BRISCΔNΔC–
SHMT2ΔN(A285T) (right). b, Representative cryo-EM micrograph. 
Green circles (180 Å diameter) indicate auto-picked particles. c, Flow chart 
of data processing. Final electron microscopy maps, coloured according 
to local resolution, are provided (scale bar in Å). d, FSC curves for the 
indicated maps. The final resolution was calculated using the  








































































Extended Data Fig. 5 | Structural analysis of BRISC–SHMT2 structures. 
a, Structural overview of the BRISCΔNΔC–SHMT2 structure and 
cryo-EM maps at a contour level of 0.085 (C2 map), showing secondary 
structure features. BRCC45 UEV-C and MERIT40 vWFA domains are 
omitted. CCHB, coiled-coil helical bundle. Asterisks mark the position of 
the BRCC36 active site. An overreaching loop (SHMT2 residues 296–307) 
is coloured red. b, Representative electron microscopy map of the BRCC36 
active site. c, d, Structure of human (c) and insect (C. floridanus) (d) 
BRCC36–Abraxas 2 superdimer, highlighting differences and similarities. 
The connectivity of the MPN- domain of Abraxas 2 and α4 helix by 
a crossover loop is different in the insect and human complexes, and 
is coloured orange in the latter structure. e, Superimposition of the 
BRCC36 MPN+ domain from the insect (grey) and human (blue, green) 
heterodimers. Abraxas-2 regions with notable differences between the two 
structures are coloured orange.
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Extended Data Fig. 6 | Analysis of SHMT1 interaction with BRISC.  
a, Elution profile of wild-type SHMT1 from an S75 16/600 size-exclusion 
chromatography column (data are representative of two independent 
experiments). b, Elution profile of SHMT1 containing mutated 
residues designed to break the tetrameric interface (left; data are from 
a single experiment). Structure of SHMT1 tetramer (PDB code 1RV4), 
highlighting residues that are important for tetramerization (right).  
c, BRISC DUB activity against a fluorogenic K63-linked diUb substrate 
in the presence of the indicated forms of SHMT1 and SHMT2. Data 
are mean ± s.e.m. of three independent experiments carried out in 
duplicate. For gel source data, see Supplementary Fig. 1. d, Coomassie-
stained SDS–PAGE analysis of the indicated SHMT1 and SHMT2 protein 
preparations (data are from a single experiment). e, Analytical size-
exclusion chromatography runs of the indicated protein preparations. 
SHMT1 proteins were mixed with BRISC for 30 min before injecting on a 
2.4-ml Superose 6 column (bottom traces). Traces on top are control runs. 
A BRISC–SHMT2ΔN run is shown for comparison (see Extended Data 
Fig. 8e for detailed analysis). f, Coomassie-stained SDS–PAGE analysis of 
the indicated peak fractions from size-exclusion runs shown in e. Data in 
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Extended Data Fig. 7 | See next page for caption.
ArticlereSeArcH
Extended Data Fig. 7 | Purification and analysis of SHMT2 mutants.  
a, Elution profile of the indicated forms of SHMT2ΔN from an S75  
10/300 size-exclusion chromatography column (single experiment).  
b, Coomassie-stained SDS–PAGE analysis of the indicated SHMT2ΔN 
protein preparations (data are representative of two independent 
experiments). c, BRISC DUB activity against a fluorogenic K63-linked 
diUb substrate in the presence of the indicated SHMT2ΔN mutants. 
Data are mean ± s.e.m. of three independent experiments carried out in 
duplicate. d, BRISC DUB activity against K63-linked hexaUb chains  
in the presence of the different forms of SHMT2ΔN, or SHMT1.  
e, Ubiquitylation levels of IFNAR1 after IFNα stimulation in HEK293T 
cells that overexpress the indicated forms of Abraxas 2 and SHMT2ΔN. 
The annotation ‘LL->RR’ denotes SHMT2ΔN(L211R/L215R). IFNAR1 
immunoprecipitation (IP) was performed under denaturing conditions 
and ubiquitin levels were detected using the vu-1 antibody. Mock IP was 
performed using a generic rabbit IgG antibody. f, Immunoprecipitation 
(IP) performed using anti-Flag antibody in MEFs that were transiently 
transfected with Flag–HA epitope-tagged SHMT2ΔN or mutants. 
Immunoblot was performed for Abraxas 2 and SHMT2, as indicated. 
UTF, untransfected cells (used as control). g, MEFs that overexpress 
the indicated SHMT2ΔN or mutants were challenged with LPS, and 
interferon-receptor-dependent signal transduction response was assessed 
by immunoblot for STAT1 phosphorylated at Y701. Data shown in  
d, e are representative of three independent experiments. For gel source 
data, see Supplementary Fig. 1.
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Extended Data Fig. 8 | See next page for caption.
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Extended Data Fig. 8 | SHMT2 blocks the BRISC active site.  
a, Analytical size-exclusion chromatography of different forms of 
SHMT2ΔN, preincubated with BRISC (left) and SDS–PAGE analysis 
of peak fractions (right). Data are representative of two independent 
experiments. b, K63-linked diUb (grey) modelled on the MPN+ domain 
of BRCC36 using the AMSH-LP–diUb structure (PDB code 2ZNV) as a 
guide. The SHMT2 obligate dimer sterically clashes with the modelled 
proximal ubiquitin. c, Michaelis–Menten (top) and Lineweaver–Burk 
(bottom) plots for BRISC DUB activity against a K63-linked diUb 
fluorogenic substrate with addition of SHMT2ΔN(A285T). Technical 
duplicates are shown and data are representative of two independent 
experiments. d, Superimposition of SHMT2 dimer and tetramer forms. 
The SHMT2 obligate dimer from the PLP-bound tetramer structure (PDB 
code 4PVF, coloured grey) was overlaid on the SHMT2ΔN(A285T) dimer 
bound to BRISC. The second obligate dimer from the SHMT2-–PLP 
holoenzyme sterically clashes with the BRCC36–Abraxas 2 superdimer. 
Movement of α6 and α7 helices is indicated. e, Analytical size-exclusion 
chromatography of SHMT2ΔN dimer and tetramer (+PLP) forms with 
BRISC (left) and SDS–PAGE analysis of peak fractions (right). Data are 
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Extended Data Fig. 9 | See next page for caption.
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Extended Data Fig. 9 | Regulation of BRISC–SHMT2 function in cells. 
a, Schematic of pairwise comparison of Abraxas2–/– MEFs treated with LPS 
and expressing the indicated forms of Abraxas 2 (top). Bar chart illustrates 
the IFN-type I-related genes that were increased by more than twofold in 
Abraxas 2 wild-type + LPS (black) and Abraxas 2(E144R) + LPS (blue), 
relative to Abraxas2-/- + LPS. Data are presented as mean ± s.e.m. from 
three independent experiments (biological replicates). b, Native gel 
electrophoresis of whole MEF cell lysates cultured in B6-vitamer-free 
medium, with and without pyridoxal, and expressing the indicated forms 
of Flag–HA–SHMT2ΔN. c, d, Measurement of phosphorylated STAT1 
levels (phosphorylated at Y701) in MEFs (c) or MEFs that stably express 
SHMT2 (d), cultured in B6-vitamer-free medium. Where indicated, cells 
were treated with 20 μM pyridoxal and/or 500 units per millilitre of IFNβ 
for 48 h. e, Immunoprecipitation performed using anti-Flag antibody in 
MEFs transiently transfected with Flag–HA epitope-tagged SHMT2 or 
mutants (cultured in DMEM). Immunoblot was performed for Abraxas 2 
and SHMT2 as indicated. f, Phosphorylated STAT1 levels (phosphorylated 
at Y701) measured in MEFs cultured in DMEM containing vitamin B6 and 
the indicated forms of SHMT, after challenge with HSV. Data shown in  
b–f are representative of three independent experiments. For gel source 




































































































































































































Extended Data Fig. 10 | Proposed model of BRISC–SHMT2 regulation 
of cytokine signalling. K63-linked poly-ubiquitylated interferon 
receptors (IFNAR1 and IFNAR2) are internalized and degraded through 
the lysosomal degradation pathway. The BRISC–SHMT2 complex is 
required for deubiquitylation of IFNAR1 and IFNAR2, and for receptor 
stabilization. BRISC deubiquitylation of IFNAR1 and IFNAR2 receptors 
proceeds after SHMT2 displacement, which leads to sustained interferon 
signalling. The SHMT2 dimer–tetramer transition is regulated by PLP 
binding. Only an inactive SHMT2 dimer can interact with BRISC, whereas 
the active SHMT2 tetramer will sterically clash with the BRCC36–
Abraxas 2 superdimer. Modulation of SHMT2 dimer–tetramer transition 
by PLP analogues or other binders could represent ways to inhibit BRISC 
recruitment to IFNAR1 and IFNAR2, and to reduce interferon signalling.
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Antibodies used Rabbit polyclonal antibodies were generated by the Greenberg lab to the following recombinant proteins: MERIT40, Abraxas2, 
BRCC36 and BRCC45.  
 
Commercially available antibodies: 
1. HA epitope (HA.11 Covance).  
2. SHMT2 (Cell Signaling).    
3. Ub (P4D1) HRP, Monoclonal Antibody (Santa Cruz)  
4. Ub VU1 antibody (Lifesensors)    
5. IFNAR1 antibody (Bethyl laboratories)  
6. Phospho-Stat1 (Tyr701) (58D6) Rabbit mAb #9167 (Cell Signalling)  
7. Stat1 Antibody #9172 (Cell Signalling)  
Validation Polyclonal antibodies were validated in house using knockout cell lines to verify that no detectable signal was observed on 
western blot in knockout cell lines for the cognate antigen. 
 
Validation date for commercially available antibodies can be found using the links below: 
1. HA epitope (HA.11 Covance). https://www.biolegend.com/fr-fr/global-elements/pdf-popup/anti-ha-11-epitope-tag-
antibody-11071?filename=Anti-HA11%20Epitope%20Tag%20Antibody.pdf&pdfgen=true  
 
2. SHMT2 (Cell Signaling). https://www.cellsignal.com/products/primary-antibodies/shmt2-antibody/12762   
 
3. Ub P4D1 (Santa Cruz). https://datasheets.scbt.com/sc-8017.pdf  
 
4. Ub VU1 (Lifesensors). https://lifesensors.com/wp-content/uploads/2017/02/VU101_VU-1Antibody_datasheet_032113.pdf  
 
5. IFNAR1 antibody (Bethyl laboratories): https://www.bethyl.com/product/A304-290A/IFNAR1+Antibody 
 
6. pSTAT1 (pY701) (Cell Signalling): https://media.cellsignal.com/pdf/9167.pdf 
 
7. STAT1 (Cell Signalling):  https://media.cellsignal.com/pdf/9172.pdf
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fibroblasts (MEFs) were generated as previously described (Zheng et al. Cell Reports2013). HEK293T cells were obtained from 
ATCC.
Authentication No authentication of Sf9 cells or HEK293T cells was carried out. Abraxas2 null mouse embryonic fibroblasts were verified by 
western blot and PCR genotyping. 
Mycoplasma contamination No mycoplasma contamination was detected using a commercial mycoplasma detection kit.
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Commonly misidentified cell lines were not used.
